Pruritus care shifts toward more tailored treatment plans

Pruritus management in dogs and cats is getting a more explicit, evidence-based playbook, with current recommendations centering on treating the underlying cause when possible, then choosing antipruritic therapy based on species, severity, comorbidities, and the need for rapid relief. In a recent Veterinary Practice News review, Therese Castillo points clinicians to the 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines and a broader evidence base that includes glucocorticoids, oclacitinib, lokivetmab, cyclosporine, topical therapy, parasite control, diet trials, and treatment of secondary infections as core tools rather than one-size-fits-all fixes. The article also reflects a fast-changing market: in the U.S., FDA approved Zenrelia (ilunocitinib) in September 2024 for control of pruritus associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months old, adding another systemic option alongside Apoquel and Cytopoint. (veterinarypracticenews.com)

Why it matters: For veterinary professionals, the message is that itch control is no longer just about stopping scratching quickly, but about balancing speed, safety, diagnostic workup, long-term disease control, and pet parent expectations. AAHA’s guidance emphasizes stepwise management of flea allergy, food allergy, canine atopic dermatitis, and feline atopic skin syndrome, while other reviews note meaningful differences among therapies: glucocorticoids act quickly but carry familiar systemic tradeoffs, oclacitinib offers rapid oral control, lokivetmab can provide fast relief with an injectable biologic approach, and cats still have fewer labeled options than dogs. Newer agents may expand choices, but they also add practical questions around patient selection, monitoring, vaccination timing, and how aggressively clinics pursue underlying diagnosis before settling into chronic symptom control. (meridian.allenpress.com)

What to watch: Expect more discussion around where newer JAK-pathway drugs fit in canine allergy algorithms, especially as clinicians weigh label indications, safety communications, and real-world use against established options. (fda.gov)